awmsg logo



bevacizumab (Avastin®)


Reference No. 1824

Publication date:
31/10/2014


Appraisal information

bevacizumab (Avastin®) 25 mg/ml concentrate for solution for infusion


Company: Roche Products Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ministerial ratification: 30/10/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, bevacizumab (Avastin®) cannot be endorsed for use within NHS Wales in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.
Statement of Advice (SOA)
Download